Business Wire

I-SQUARED-CAPITAL

Share
I Squared Capital Establishes a Renewable Energy Platform, Cube Green Energy

I Squared Capital, a leading global infrastructure investor, has established Cube Green Energy, a renewable energy platform dedicated to accelerating the energy transition to a zero-carbon economy. The platform will develop, repower, construct, and operate wind and solar farms, as well as invest in the deployment of associated emerging technologies such as battery storage and green hydrogen. Cube Green Energy’s initial focus will be the mature renewables markets in Continental Europe that are at the forefront of the energy transition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004006042/en/

Cube Green Energy is led by former senior executives from GE Energy Financial Services (GE EFS), the energy investment arm of General Electric Company, with over 70 years combined global power markets experience including more than 40 years in renewable energy.

Cube Green Energy CEO, Raghuveer Kurada, has held various leadership roles at GE EFS, including successfully closing and managing over $10 billion of value-accretive investments globally as Head of Global Deal Execution. Most recently, he was responsible for raising over $6 billion in third-party equity and debt for GE projects as Head of Global Capital Advisory.

The other members of the management team include Sharad Jain, Niko Meissner, and Hussain Shalchi. Sharad Jain has over 25 years and 15+ GW of global energy sector investment experience and brings deep domain knowledge in asset investment, management and financial structuring. Niko Meissner has more than 15 years of renewables development experience with GE Power, GE EFS, Vestas and, most recently, Aquila Capital having managed the development of over 6 GW of power generation capacity and will be instrumental in establishing the German operations which is one of the largest target markets. Hussain Shalchi has held various senior positions in the energy sector including acting as Managing Director and Global Counsel at GE EFS and, most recently, as Head of Strategic Joint Venture at Ørsted.

“I Squared Capital has invested over $6.5 billion in transition energy, including $4 billion in 12 renewable energy companies globally since 2014, and we are continuing that strategy with a world-class management team that brings deep experience, industry knowledge and on the ground presence to address an unmet market demand,” said Gautam Bhandari, Managing Partner at I Squared Capital. “Using our platform building strategy, we look to initially commit up to $500 million over the coming years to build Cube Green Energy into a leading renewables company that can help enable Europe’s transition to a zero-carbon economy.”

“Companies and governments must innovate to replace base load power with renewables to meet ambitious climate targets,” said Raghuveer Kurada, CEO, Cube Green Energy. “With a mandate to invest in more efficient and emerging technologies and sector expertise across the project cycle, Cube Green Energy and I Squared Capital are well placed to enable the Renewables 2.0 transition in Continental Europe and beyond.”

About I Squared Capital

I Squared Capital is an independent global infrastructure investment manager with over $30 billion in assets under management focusing on energy, utilities, digital infrastructure, transport and social infrastructure in North America, Europe, Latin America and Asia. The firm has offices in Miami, Hong Kong, London, New Delhi, and Singapore.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye